In 2009, the Food and Drug Administration approved the clinical use of OVA-1, a serum test analyzing five biomarkers: CA-125, II-microglobulin (both elevated in ovarian cancer), apolipoprotein A1, prealbumin (transthyretin), and transferrin (which are decreased in ovarian cancer). Here, APOA1 is linked to ovarian cancer.